Navigation Links
CuraGen to Present at the BIO CEO & Investor Conference
Date:2/12/2008

BRANFORD, Conn., Feb. 12 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN) announced today that Timothy M. Shannon, M.D., President and Chief Executive Officer, will present at the BIO CEO & Investor Conference on Wednesday, February 13, 2008, at 3:30 p.m. Eastern Standard Time.

Access to a live webcast of the presentation will be available at http://www.curagen.com. A replay of the webcast will be accessible beginning one hour after the presentation and available on the Company's website until March 13, 2008.

About CuraGen

CuraGen Corporation (Nasdaq: CRGN) is a dedicated clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer including the histone deacetylase inhibitor, belinostat, and the antibody-drug conjugate, CR011-vcMMAE. By leveraging drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of cancer patients. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit http://www.curagen.com.

Contacts:

Glenn Schulman, PharmD

Director of Investor Relations

gschulman@curagen.com

(888) 436-6642

CRGN-G


'/>"/>
SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. CuraGen Reports Fourth Quarter and Year End 2007 Financial Results
2. CuraGen Corporation Receives Notification from NASDAQ
3. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
4. CuraGen and TopoTarget Announce Initiation of an NCI-sponsored Phase II Clinical Trial of Belinostat for Thymoma and Thymic Carcinoma
5. CuraGen to Present at the 19th Annual Piper Jaffray Health Care Conference
6. CuraGen Appoints Clinical Oncologist as VP of Medical Development
7. CuraGen Corporation Announces Appointment of Dr. Timothy M. Shannon as President and Chief Executive Officer
8. Maxygen to Present at the Roth 20th Annual OC Growth Stock Conference
9. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
10. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
11. Emisphere Technologies to Web Cast BIO CEO & Investor Conference Presentation February 12
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
(Date:6/23/2016)... NC (PRWEB) , ... June 23, 2016 , ... In ... University Hospital in Denmark detail how a patient who developed lymphedema after being treated ... tissue. The results could change the paradigm for dealing with this debilitating, frequent side ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology:
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
Breaking Biology News(10 mins):